Best Practice & Research Clinical Rheumatology
Volume 22, Issue 2 , Pages 311-323, April 2008

Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials

Division of Clinical Immunology and Rheumatology, Academic Medical Centre/University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

The analysis of synovial biomarkers is increasingly used in the context of innovative trial design in rheumatoid arthritis (RA). This approach, which is generally well tolerated by patients, has been used to provide insight into the pathogenesis of RA and the mechanism of action of therapy, as well as for screening purposes during early drug development.

Key words: anti-TNF treatment, biomarkers, chemokine receptors, chemokines, rheumatoid arthritis, rituximab, synovial tissue, treatment

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6942(08)00014-4

doi:10.1016/j.berh.2008.02.002

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 2 , Pages 311-323, April 2008

Article Tools

* Image Usage & Resolution